Skip to main content
SpringerLink
Log in

Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) über Fälle von Malignomen bei Anti-TNF-behandelten Patienten

Comment of the Society of Pediatric and Adolescent Rheumatology on the US Food and Drug Administration (FDA) announcement regarding cases of malignancy in anti-TNF-treated patients

  • Standpunkte
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Alonso-Ruiz A, Pijoan JI et al (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9:52

    Article  PubMed  Google Scholar 

  2. Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339

    Article  PubMed  CAS  Google Scholar 

  3. Askling J, Baecklund E et al (2008) Anti-TNF therapy in RA and risk of malignant lymphomas relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis [Epub ahead of print, May 8]

  4. Askling J, Fored C M et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426

    Article  PubMed  CAS  Google Scholar 

  5. Baecklund E, Iliadou A et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701

    Article  PubMed  Google Scholar 

  6. Bongartz T, Sutton A J et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285

    Article  PubMed  CAS  Google Scholar 

  7. Bielack S (2007) Leukämien und maligne Knochentumoren. In: Wagner N, Dannecker G (Hrsg) Pädiatrische Rheumatologie, Springer, Berlin Heidelberg New York Tokyo

  8. Brown S L, Greene M H et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158

    Article  PubMed  CAS  Google Scholar 

  9. Cabral DA, Tucker LB (1999) Malignancies in children who initially present with rheumatic complaints. J Pediatr 134:53–57

    Article  PubMed  CAS  Google Scholar 

  10. Carmona L, Descalzo MA et al (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880–885

    Article  PubMed  CAS  Google Scholar 

  11. Gartlehner G, Hansen R A et al (2008) Biologics for the treatment of juvenile idiopathic arthritis: A systematic review and critical analysis of the evidence. Clin Rheumatol 27:67–76

    Article  PubMed  Google Scholar 

  12. Geborek P, Bladstrom A et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703

    Article  PubMed  CAS  Google Scholar 

  13. Goncalves M, Terreri MTRA, Barbosa CMPL et al (2005) Diangosis of malignancies in children with musculoskeletal complaints. Sao Paulo Med J 123:21–23

    PubMed  Google Scholar 

  14. Horneff G, De Bock F et al (2008) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the german JIA Registry. Ann Rheum Dis [Epub ahead of print, April 15]

  15. Imundo L (2008) Hodgkin’s lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: Supplemental case report. J Rheumatol 35:1681

    PubMed  Google Scholar 

  16. Lovell DJ, Reiff A et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504

    Article  PubMed  CAS  Google Scholar 

  17. Moreland LW, Weinblatt ME et al (2006) Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33:854–861

    PubMed  CAS  Google Scholar 

  18. Prince FH, Twilt M et al (2008) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis [Epub ahead of print, April 15]

  19. Schiff MH, Burmester GR et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889–894

    Article  PubMed  CAS  Google Scholar 

  20. Schiff M, Keiserman M et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103

    Article  PubMed  CAS  Google Scholar 

  21. Setoguchi S, Solomon DH et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764

    Article  PubMed  CAS  Google Scholar 

  22. Trapani S, Grisolia F, Simonini G et al (2000) Incidence of occult cancer in children presenting with musculoskeletal symptoms: A 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum 29:348–359

    Article  PubMed  CAS  Google Scholar 

  23. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 56:2886–2895

    Article  PubMed  Google Scholar 

  24. Yildirim-Toruner C, Kimura Y et al (2008) Hodgkin’s lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol 35:1680–1681

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Forschungsförderung durch Wyeth, Abbott-Pharma.

Author information

Authors and Affiliations

  1. Olgahospital-Kinderklinik, Stuttgart, Deutschland

    T. Hospach & G. Dannecker

  2. Universitätskinderklinik, Greifswald, Deutschland

    J.P. Haas

  3. Prof. Hess Kinderklinik, Bremen, Deutschland

    H.I. Huppertz

  4. Charité, Berlin, Deutschland

    R. Keitzer

  5. Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Deutschland

    H. Michels

  6. Helios Klinikum Berlin-Buch, Berlin, Deutschland

    R. Trauzeddl

  7. Universitätskinderklinik, Münster, Deutschland

    D. Föll

  8. Zentrum für Allgemeine Pädiatrie und Neonatologie, Asklepios Klinik Sankt Augustin, Arnold-Janssen Str. 29, 53757, Sankt Augustin, Deutschland

    G. Horneff

Authors
  1. T. Hospach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.P. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.I. Huppertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Keitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Michels
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Trauzeddl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Föll
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Dannecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Horneff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Horneff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hospach, T., Haas, J., Huppertz, H. et al. Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) über Fälle von Malignomen bei Anti-TNF-behandelten Patienten. Z. Rheumatol. 68, 162–164 (2009). https://doi.org/10.1007/s00393-008-0426-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-008-0426-y

Search

Navigation